SGLT2i在心力衰竭管理中的当前地位:来自印度的专家意见
H K Chopra1, Tiny Nair2, G S Wander3
1Senior Consultant, Department of Cardiology, Medanta Moolchand Heart Center, Delhi, India.
概括
-葡萄糖携带载体-2 抑制剂 (SGLT2i) 对心力衰竭 (HF) 患者,包括2型糖尿病患者,提供显著的心血管益处. 这些SGLT2i药物改善了心脏功能,并减少了更广泛的HF人群的不良结果.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一个重大的全球健康挑战,在印度的流行率很高,经常影响2型糖尿病 (T2DM) 的年轻人.
- 大约50%的印度HF患者患有并发症T2DM,突出显示了这些疾病的关键交叉点.
研究的目的:
- 审查有关SGLT2i抑制剂 (Sodium-glucose cotransporter-2 inhibitors (SGLT2i)) 治疗心力衰竭 (HF) 的有效性和安全性的最新证据.
- 建议将SGLT2i整合到高频率治疗指南中,特别关注印度患者群体.
主要方法:
- 对当前临床证据和临床试验数据的系统审查,这些证据和试验数据涉及HF患者的SGLT2i.
- 分析SGLT2i在不同HF人群中超出血糖控制的心血管 (CV) 益处.
主要成果:
- 在HF患者中,SGLT2i显示出实质性的心血管益处,独立于他们的血糖控制状态.
- 用SGLT2i和指导方针指导的医学疗法 (GMDT) 进行的联合治疗显示了增强心脏功能和减轻HF不良事件的附加效应.
- 证据支持SGLT2i在广泛的HF患者中使用,包括患有和没有糖尿病的患者,无论射出分数 (EF) 是否.
结论:
- 建议SGLT2i作为心力衰竭管理的有价值的治疗选择.
- 这些益处扩展到广泛的HF人群,包括2型糖尿病患者,并且无论射出分数如何,都有效.
- 重点是SGLT2i对患有心力衰竭的印度患者的实用性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:26Heart Failure Drugs: Inotropic Agents
573
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
01:22Heart Failure Drugs: Diuretics
367
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
367
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K